Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
This is a single arm, interventional pilot study of using chlorhexidine irrigation
intra-operatively and post-operatively among patients undergoing radical cystectomy with
urinary diversion. The intervention comprises of using irrigation of ileal conduit or
ileal neo...
Age: 18 years - 66+
Gender: All
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors
including urothelial cancer. The study is conducted in two parts - phase Ia
(dose-escalation, dose-o...
Age: 18 years - 66+
Gender: All
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the future, as standard screening measure. Adult...
Age: 18 - 89 years
Gender: All
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Researchers are looking for new ways to treat people with high-risk muscle-invasive
urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins
in cells that line the inside of the bladder and other parts of the urinary tract, such
as pa...
Age: 18 years - 66+
Gender: All
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line
the urinary system and other solid tumor cancers that have a change in a particular gene
(known ...
Age: 18 years - 66+
Gender: All
Intravesical BCG vs GEMDOCE in NMIBC
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC)
patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a
non-inferior event-free survival (EFS) compared to standard treatment with intravesical
BCG. The pu...
Age: 18 years - 66+
Gender: All
Pembrolizumab in Muscle-invasive Bladder Cancer
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After
completing two cycles of pembrolizumab, subjects will undergo a restaging MRI of the
abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as
well as CT ...
Age: 18 years - 66+
Gender: All
The Personal Patient Profile Decision Support for Patients With Bladder Cancer
There is a pressing need to develop a personalized, value-based decisional tool for bladder
cancer patients undergoing radical cystectomy (bladder removal) and urinary diversion to help
them with communication with the physicians, shared decision making, and prepara...
Age: 18 years - 66+
Gender: All
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination
with intravenous (IV) cetrelimab and IV cetrelimab alone.
Age: 18 years - 66+
Gender: All
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative
enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node
dissection (PLND) compared with the current standard of care (neoadjuvant chemotherap...
Age: 18 years - 66+
Gender: All
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative
enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node
dissection (PLND) compared with the current standard of care (neoadjuvant chemotherap...
Age: 18 years - 66+
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study
of BT8009 given as a single agent and in combination with pembrolizumab in participants
with advanced solid tumors associated with Nectin-4 expression or in participants with
ad...
Age: 18 years - 66+
Gender: All
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial
of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with
metastatic urothelial cancer who have achieved at least stable disease on first-line...
Age: 18 years - 66+
Gender: All